,
“Does malnutrition affect survival in cirrhosis? PINC (Policentrica Italiana Nutrizione Cirrosi).”, Hepatology, vol. 23, no. 5, pp. 1041-6, 1996.
, “Protection against sexually transmitted diseases by granting sex workers in Thailand the choice of using the male or female condom: results from a randomized controlled trial”, AIDS, vol. 12, pp. 1851-9, 1998.
, “Protection against sexually transmitted diseases by granting sex workers in Thailand the choice of using the male or female condom: results from a randomized controlled trial.”, AIDS, vol. 12, no. 14, pp. 1851-9, 1998.
, “Safety evaluation of nonoxynol-9 gel in women at low risk of HIV infection”, AIDS, vol. 12, pp. 433-7, 1998.
, “Safety evaluation of nonoxynol-9 gel in women at low risk of HIV infection.”, AIDS, vol. 12, no. 4, pp. 433-7, 1998.
, “Cancer prevalence in Italian regions with local cancer registries”, Tumori, vol. 85, pp. 400-7, 1999.
, “Clinical and immuno-virologic characterization of the efficacy of stavudine, lamivudine, and indinavir in human immunodeficiency virus infection”, J Pediatric, vol. 135, pp. 675-82, 1999.
, “Clinical and immuno-virologic characterization of the efficacy of stavudine, lamivudine, and indinavir in human immunodeficiency virus infection.”, J Pediatr, vol. 135, no. 6, pp. 675-82, 1999.
, “The Advanced Glaucoma Intervention Study (AGIS): 14. Distinguishing Progression of Glaucoma from Visual Field Fluctuations”, Ophthalmology, vol. 111, pp. 2109-2116, 2004.
, , “Challenges Experienced By the Clinical Team During The Conduct of HIV Vaccine Clinical Trials in Kenya”, in AIDS Vaccine 2005 International Conference, Montreal, Quebec, Canada, 2005.
, “Phase 2A Dose and Route Study of a DNA Prime MVA Boost Vaccine Candidate”, in AIDS Vaccine 2005 International Conference, Montreal, Quebec, Canada, 2005.
, “Safety and Immunogenicity of MVA.HIVA by 3 Different Routes”, in AIDS Vaccine 2005 International Conference, Montreal, Quebec, Canada, 2005.
, ,
“A Phase 2 Study to Evaluate the Safety and Immunogenicity of a Recombinant Adeno-Associated Virus HIV Vaccine”, in AIDS Vaccine 2007 Conference, Seattle, WA, 2007.
, “Safety and Immunogenicity of VRC Multiclade HIV-1 Adenoviral Vector Vaccine Alone or with VRC Multiclade HIV-1 DNA Plasmid Vaccine in the African Adults”, in AIDS Vaccine 2007 Conference, Seattle, WA, 2007.
, , “Baseline Morbidity in 2,990 Adult African Volunteers Recruited to Characterize Laboratory Reference Intervals for Future HIV Vaccine Clinical Trials”, PLoS ONE, vol. 3, p. e2043, 2008.
, “A Cross-Sectional Study in Eastern and Southern Africa to Characterize Laboratory Reference Intervals in Healthy Adults for HIV Prevention Trials”, in AIDS Vaccine 2008 Conference, Cape Town, South Africa, 2008.
, , “Phase 1 Safety and Immunogenicity Evaluation of ADVAX a Multigenic, DNA-Based Clade C/B’ HIV-1 Candidate Vaccine”, PLoS ONE, vol. 5, p. e8617, 2010.
, “Safety and Immunogenicity Study of Multiclade HIV-1 Adeno-Viral Vector Vaccine Alone or as Boost Following a Multiclade HIV-1 DNA Vaccine in Africa”, PLoS ONE, vol. 5, p. e12873, 2010.
, “Viral Inhibition Assay: A CD8 T Cell Neutralization Assay for Use in Clinical Trials of Human Immunodeficiency Virus-1 Vaccine Candidates”, J Infect Dis, vol. 201, pp. 720-729, 2010.
,